10-Q · May 8, 2026
bioAffinity Technologies reported a Q1 2026 revenue of approximately $1.4 million, a decline of 27% year-over-year and a miss from the consensus estimate. While the company's CyPath® Lung unit sales surged 146%, overall…
Earnings analysis · 10-Q
BIAF earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Q2 2026 revenue was $1.511 million and diluted EPS was negative $0.64; the supplied quarterly history indicates revenue remained near the $1 million level seen in Q2 2025 and Q1 2026, while profitability remained deeply…
Read full summary
Q2 2026 revenue was $1.511 million and diluted EPS was negative $0.64; the supplied quarterly history indicates revenue remained near the $1 million level seen in Q2 2025 and Q1 2026, while profitability remained deeply negative. The filing’s primary signal is liquidity stress: cash declined from $2.4 million at June 30, 2026 to $1.0 million on August 3, 2026, and management cited substantial doubt about continuing as a going concern for at least twelve months. A new Nasdaq deficiency notice dated July 30, 2026 further increases financing and trading risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.64
What stood out
-
Commercial revenue remains established
The company reported approximately $2.9 million of revenue during the six months ended June 30, 2026, compared with $6.2 million during 2025, providing a specific measure of its commercial laboratory activity.
-
Disclosure controls remain effective
Management assessed disclosure controls and procedures as effective as of June 30, 2026, and reported no changes during the three months ended June 30, 2026 that could materially affect internal control over financial reporting.
What to watch
-
Severe liquidity and going-concern risk
Cash and liquidity deteriorated materially: cash was $2.4 million as of June 30, 2026 but only $1.0 million as of August 3, 2026. Management stated that, without additional funding, resources were sufficient to continue operations only through August 2026 and identified substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
-
Nasdaq minimum-bid-price deficiency
The company disclosed a new Nasdaq listing risk after receiving notice on July 30, 2026 that its securities had closed below the $1.00 minimum bid price for 30 consecutive business days. Because of a prior 1-for-30 reverse stock split on September 19, 2025, the company was not eligible for the standard 180-calendar-day compliance period.
-
Additional financing remains essential
The company reported an accumulated deficit of $75.6 million as of June 30, 2026 and stated that it must raise additional capital through equity, debt, strategic relationships, grants, or other arrangements to support operations. Failure to obtain funding could require it to curtail or cease operations.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that, without additional funding, cash resources were expected to support operations through August 2026 and concluded there was substantial doubt about continuing as a going concern for at least twelve months.
Earlier filings 4
10-K · March 16, 2026
bioAffinity’s 2025 10-K shows the company actively refocusing toward its CyPath® Lung diagnostic: consolidated revenue fell ~34% to $6.2 million as management discontinued unprofitable pathology services, while CyPath®…
10-Q · November 14, 2025
bioAffinity reported Q3 2025 revenue of $1,446,066 (down from $2,350,386 in Q3 2024) and a GAAP net loss of $5,051,084 (loss per share $(4.74)). The company materially strengthened its liquidity in Q3 via financing…
10-K · March 31, 2025
bioAffinity’s 2024 results reflect a revenue inflection driven by the September 2023 acquisition of PPLS: consolidated revenue rose approximately 270% to $9.4 million for the year ended December 31, 2024. The company is…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.